A Centers for Disease Control and Prevention study reveals that 3 out of 4 U.S HIV/AIDS patients struggle to maintain a proper medication regime to treat their disease because of the high cost

TITUSVILLE, New Jersey, September 23, 2011 /PRNewswire/ -- - Third HIV medication submitted by Tibotec - Tibotec Pharmaceuticals (Tibotec), one of the Janssen

PITTSBURGH, Sept. 20, 2011 /PRNewswire/ -- Mylan Inc. (Nasdaq: MYL) today announced that its subsidiary Matrix Laboratories Limited has received tentative approval from the U.S.

TITUSVILLE, N.J., July 19, 2011 /PRNewswire/ -- Janssen Therapeutics, Division of Janssen Products, LP, presented today 96-week findings from two pivotal Phase 3 clinical trials, known as ECHO and THRIVE, comparing the efficacy, safety and virology profile of its non-nucleoside reverse transcriptase inhibitor (NNRTI) EDURANT(TM) (rilpivirine) tablets versus efavirenz (EFV) in antiretroviral treatment-naive, HIV-1-infected adults.

TITUSVILLE, N.J., May 20, 2011 /PRNewswire/ -- The US Food and Drug Administration (FDA) today approved EDURANT(TM) (rilpivirine) tablets for use in combination with other antiretroviral agents (ARVs) in the treatment of human immunodeficiency virus type 1 (HIV-1) in adults who have never taken HIV therapy (treatment-naive).